The new and recurrent FLT3 juxtamembrane deletion mutation shows a dominant negative effect on the wild-type FLT3 receptor-Reference-Cited by-同舟云学术

The new and recurrent FLT3 juxtamembrane deletion mutation shows a dominant negative effect on the wild-type FLT3 receptor

Published:2016-06-27 Issue:1 Volume:6 Page:
ISSN:2045-2322
Container-title:Scientific Reports
language:en
Short-container-title:Sci Rep

Author:

Sandhöfer Nadine,Bauer Julia,Reiter Katrin,Dufour Annika,Rothenberg Maja,Konstandin Nikola P.,Zellmeier Evelyn,Tizazu Belay,Greif Philipp A.,Metzeler Klaus H.,Hiddemann Wolfgang,Polzer Harald,Spiekermann Karsten

Publisher

Springer Science and Business Media LLC

Subject

Multidisciplinary

Link

http://www.nature.com/articles/srep28032.pdf

Reference15 articles.

1. Schnittger, S. et al. Analysis of FLT3 length mutations in 1003 patients with acute myeloid leukemia: correlation to cytogenetics, FAB subtype and prognosis in the AMLCG study and usefulness as a marker for the detection of minimal residual disease. Blood. 100(1), 59–66 (2002).

2. Thiede, C. et al. Analysis of FLT3-activating mutations in 979 patients with acute myelogenous leukemia: association with FAB subtypes and identification of subgroups with poor prognosis. Blood. 99(12), 4326–35 (2002).

3. Kiyoi, H. et al. Internal tandem duplication of the FLT3 gene is a novel modality of elongation mutation which causes constitutive activation of the product. Leukemia. 12(9), 1333–7 (1998).

4. Yamamoto, Y. et al. Activating mutation of D835 within the activation loop of FLT3 in human hematologic malignancies. Blood. 97(8), 2434–9 (2001).

5. Frohling, S. et al. Identification of driver and passenger mutations of FLT3 by high-throughput DNA sequence analysis and functional assessment of candidate alleles. Cancer Cell. 12(6), 501–13 (2007).

Cited by 13 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Characterisation of FLT3 alterations in childhood acute lymphoblastic leukaemia;British Journal of Cancer;2023-12-04

2. Mutation spectrum of FLT3 and significance of non‐canonical FLT3 mutations in haematological malignancy;British Journal of Haematology;2023-05-28

3. Therapeutic Targeting of FLT3 in Acute Myeloid Leukemia: Current Status and Novel Approaches;OncoTargets and Therapy;2022-11

4. A review of FLT3 inhibitors in acute myeloid leukemia;Blood Reviews;2022-03

5. Introduction to Target Validation;Drug Target Selection and Validation;2022